by B2i | Mar 9, 2021 | Press Releases
Results demonstrate that Dyadic’s C1 platform produced record levels of safe and effective vaccines in animal trials and further positions C1 products for potential human clinical trialsJUPITER, Fla., March 09, 2021 — Dyadic International, Inc....
by B2i | Feb 15, 2021 | Press Releases
JUPITER, FL / February 15, 2021 / Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ:DYAI) a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to...
by B2i | Feb 3, 2021 | Press Releases
JUPITER, FL / February 3, 2021 / Dyadic International, Inc. (“Dyadic”) (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs,...
by B2i | Feb 2, 2021 | Press Releases
JUPITER, FL / February 2, 2021 / Dyadic International, Inc. (“Dyadic”) (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs,...
by B2i | Jan 11, 2021 | Press Releases
JUPITER, FL / January 11, 2021 / Dyadic International, Inc. (“Dyadic”) (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs,...
by B2i | Dec 9, 2020 | Press Releases
JUPITER, FL / December 9, 2020 / Dyadic International, Inc. (“Dyadic” or the “Company”) (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate...
